Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain

Josep Maria Ribera Santasusana,1 Alejandra de Andrés Saldaña,2 Nuria García-Muñoz,3 Joana Gostkorzewicz,2 Diana Martínez Llinàs,3 Cristina Díaz de Heredia4 1Clinical Hematology Department, Catalan Institute of Oncology - Ho...

Full description

Bibliographic Details
Main Authors: Ribera Santasusana JM, de Andrés Saldaña A, García-Muñoz N, Gostkorzewicz J, Martínez Llinàs D, Díaz de Heredia C
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
all
cost-effectiveness
tisagenlecleucel
acute lymphoblastic leukaemia
spain
car-t
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-tisagenlecleucel-in-the-treatment-of-re-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-tisagenlecleucel-in-the-treatment-of-re-peer-reviewed-article-CEOR

Similar Items